Brief: FDA declines Humanigen's EUA Request for Lenzilumab in Hospitalized COVID Patients

Humanigen

09/09/2021 05:20

Sept 9 (Reuters) - Humanigen Inc  HGEN.O :
    * FDA HAS DECLINED HUMANIGEN’S EMERGENCY USE AUTHORIZATION
(EUA)
REQUEST FOR LENZILUMAB IN HOSPITALIZED COVID-19 PATIENTS
    * HUMANIGEN - FDA HAS DECLINED ITS REQUEST FOR EMERGENCY USE
AUTHORIZATION OF LENZILUMAB TO TREAT NEWLY HOSPITALIZED COVID-19
PATIENTS
    * NIH'S ACTIV-5/BET-B STUDY IS EXPECTED TO PROVIDE FURTHER
DATA
THAT MAY SUPPORT A NEW EUA REQUEST
    * HUMANIGEN - FDA STATED IT WAS UNABLE TO CONCLUDE
KNOWN&POTENTIAL
BENEFITS OF LENZILUMAB OUTWEIGH KNOWN&POTENTIAL RISKS OF USE FOR
COVID19 TREATMENT

Source text for Eikon:  ID:nBw1C3Ctqa 
Further company coverage:  HGEN.O 

 ((Reuters.Briefs@thomsonreuters.com;))